Celecoxib inhibits the COX-2/PGE2 signaling pathway, reduces vascular endothelial growth factor (VEGF) expression, and suppresses the proliferation, growth, and metastasis of head and neck cancer cells, while also decreasing PGE2-mediated immune escape (Chiang et al., 2020). The gene discussed is VEGFA; the disease is head and neck cancer.